Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 14-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules, 25 mg and 50 mg.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 14-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules, 25 mg and 50 mg.